Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Taysha Gene Therapies ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Taysha Gene Therapies EBITDA 2020-2025 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Taysha Gene Therapies ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$15.5B
Dr Reddy's Laboratories (RDY)	$11.4B
BridgeBio Pharma (BBIO)	$6.4B
Bausch Health Cos (BHC)	$1.9B
Supernus Pharmaceuticals (SUPN)	$1.7B
Amphastar Pharmaceuticals (AMPH)	$1.1B
Personalis (PSNL)	$282M
Assembly Biosciences (ASMB)	$75M
Sol-Gel Technologies (SLGL)	$15M
Evoke Pharma (EVOK)	$3M
Teligent (TLGT)	$0M